Alpha Sense BI

MARCH 26, 2025

Surges in 2024 across the APAC region including China, India, Malaysia, and South Korea have set the tone for a year of high-profile listings, with renewed investor confidence fueling a wave of public offerings. After a turbulent few years, the Asia-Pacific (APAC) IPO market is set for a major comeback in 2025.

Commerce 59

Commerce Pharmaceutical Capital Biotech 59

Alpha Sense BI

MARCH 28, 2023

The executives at AlphaSights analyze your requirements, perform market research , tally expert profiles, and finally recommend superior profiles that mostly resolve your initial query. How do various industries benefit from expert networks?

Value Chain 52

Value Chain Biotech Research Competitive 52

Alpha Sense BI

JANUARY 25, 2023

Moderna and BioTech, the pharmaceuticals companies behind the Moderna vaccines for the COVID-19 virus, just announced a new treatment this past December that would greatly reduce the chances of death from melanoma — stirring up substantial interest in investors to funnel capital. a potential cure for skin cancer.

Biotech 96

Biotech Pharmaceutical Hospitals Market Intelligence 96

Alpha Sense BI

JANUARY 26, 2024

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital.

Biotech 59

Biotech Research Loss Algorithm 59

Alpha Sense BI

NOVEMBER 9, 2022

A lot of the improvements that I talked about on a macro level, capital efficiency, operations improvements are as important internationally as they are in North America.” – Brian T. M&A IPOs to watch in Pharma and Biotech. Capital deployment and business development were a big focus during the call. BP PLC [BP].

Sales 52

Sales Loss Capital Biotech 52

Alpha Sense BI

JANUARY 8, 2025

RFK), have clouded 2025 visibility for the healthcare sector and generated a mix of expectations for healthcare systems and providers, health insurers, and biotech/pharma companies. Director with a large managed care organization Biotech and Pharma The Trump administration is expected to bring a relaxation of antitrust enforcement.

Innovation 69

Innovation Biotech Pharmaceutical Benchmarking 69